Takeda Pharmaceutical Company Ltd
- Country
- π―π΅Japan
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
- First Posted Date
- 2021-03-03
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Takeda
- Target Recruit Count
- 120
- Registration Number
- NCT04779320
- Locations
- πΊπΈ
Cedars Sinai Medical Center, Los Angeles, California, United States
πΊπΈUniversity Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
πΊπΈI.H.S Health LLC, Kissimmee, Florida, United States
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)
- First Posted Date
- 2021-03-03
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Takeda
- Target Recruit Count
- 120
- Registration Number
- NCT04779307
- Locations
- π§πͺ
UZ Antwerpen, Edegem, Antwerpen, Belgium
π§πͺUniversitair Ziekenhuis Brussel - PIN, Jette, Brussels, Belgium
πΊπΈPhoenix Childrens Hospital -1919 E Thompson Rd, Phoenix, Arizona, United States
A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)
- Conditions
- Relapsed and/or Refractory Multiple Myeloma (RRMM)
- Interventions
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 27
- Registration Number
- NCT04776018
- Locations
- πΊπΈ
Mayo Clinic Arizona - PPDS, Scottsdale, Arizona, United States
πΊπΈMayo Clinic Jacksonville - PPDS, Jacksonville, Florida, United States
πΊπΈWeill Cornell Medical Center, New York, New York, United States
A Study of Prucalopride For Functional Constipation in Children and Teenagers
- First Posted Date
- 2021-02-18
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Takeda
- Target Recruit Count
- 175
- Registration Number
- NCT04759833
- Locations
- πΊπΈ
Pediatric & Adult Research Center, Kissimmee, Florida, United States
πΊπΈThe University of Chicago Medical Center, Chicago, Illinois, United States
πΊπΈCleveland Clinic, Cleveland, Ohio, United States
A Study of Vonoprazan in Adults With Helicobacter Pylori
- Conditions
- Helicobacter Pylori
- Interventions
- First Posted Date
- 2021-02-15
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- Takeda
- Target Recruit Count
- 44
- Registration Number
- NCT04753437
- Locations
- π¨π³
West China Hospital, Sichuan University, Phase I Unit, Chengdu, Sichuan, China
A Study of Different Forms of TAK-994 in Healthy Adults
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2021-04-22
- Lead Sponsor
- Takeda
- Target Recruit Count
- 54
- Registration Number
- NCT04745767
- Locations
- πΊπΈ
Celerion Lincoln, NE site, Lincoln, Nebraska, United States
πΊπΈCelerion Tempe, AZ site, Tempe, Arizona, United States
A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease
- First Posted Date
- 2021-02-04
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Takeda
- Target Recruit Count
- 158
- Registration Number
- NCT04738942
- Locations
- π―π΅
Institute of Science Tokyo Hospital, Bunkyo-ku, Tokyo, Japan
π―π΅Ieda Hospital, Toyota, Aichi, Japan
π―π΅Hirosaki University Hospital, Hirosaki, Aomori, Japan
A Study of TAK-510 in Healthy Adults
- First Posted Date
- 2021-02-01
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Takeda
- Target Recruit Count
- 124
- Registration Number
- NCT04731922
- Locations
- πΊπΈ
PPD Development, LP, Austin, Texas, United States
A Study of Enzyme Replacement Therapy (VPRIV) in People With Type 1 Gaucher Disease Who Were Previously Treated With Substrate Reduction Therapy
- Conditions
- Gaucher Disease
- Interventions
- Other: Digital Engagement Application (GD App)Other: No Intervention
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Takeda
- Target Recruit Count
- 4
- Registration Number
- NCT04718779
- Locations
- πΊπΈ
The Lysosomal and Rare Disorders Research and Treatment Center, Fairfax, Virginia, United States
A Study of Velaglucerase Alfa (VPRIV) Given as Standard Patient Care in Young Children With Gaucher Disease
- Conditions
- Gaucher Disease
- Interventions
- Other: Standard of Care
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Takeda
- Target Recruit Count
- 11
- Registration Number
- NCT04721366
- Locations
- πΊπΈ
Lysosomal & Rare Disorders Research & Treatment Center, Fairfax, Virginia, United States